About ArriVent Biopharma
ArriVent is a biopharmaceutical company developing pharmaceutical products to cure presently untreatable cancer.
Company details
Funding
Total raised
$465M
Last stage
Public
Investors
Founders
Bing Yao
Accomplished executive and scientist with 20+ years in biopharma. Previously Chairman & CEO of Viela Bio (acquired by Horizon Therapeutics for $3.1B in 2021), and prior roles at MedImmune and AstraZeneca.
Robin LaChapelle
Experienced executive in strategic planning, HR, and capital raising. Previously Founder and Executive Director at RLT Consulting and VP of Human Resources at MedImmune/AstraZeneca North America.
Stuart Lutzker
Listed as President and Co-founder at ArriVent Biopharma.
Zhengbin (Bing) Yao
Former CEO & Chairman of Viela Bio (acquired by Horizon Therapeutics for $3.1B in 2021); previously SVP at MedImmune and SVP Head of Immuno-Oncology Franchise at AstraZeneca. Has 20+ years in biopharma.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.